Blood Res.  2017 Jun;52(2):125-129. 10.5045/br.2017.52.2.125.

Clinical characteristics, treatment, and outcome of primary rectal lymphoma: a single center experience of 16 patients

• Jeong JH
• Kim S
• Kim JE
• Yoon DH
• Lee SW
• Huh J
• Suh C

• KMID: 2413330
• DOI: http://doi.org/10.5045/br.2017.52.2.125

Abstract

BACKGROUND
The rectum is a relatively uncommon site for lymphoma compared with other gastrointestinal sites; no consensus regarding management of primary rectal lymphoma (PRL) has been formed due to its limited frequency. We aimed to investigate clinical characteristics and treatment outcomes in patients with PRL in a single center patient cohort.
METHODS
We retrospectively analyzed the results of 16 consecutive patients with PRL, identified and treated at the Asan Medical Center, Seoul, Korea between January 1993 and December 2014.
RESULTS
These 16 patients with PRL constituted 0.8% of all non-Hodgkin's lymphoma patients (N=1,984). B-cell lymphomas (N=14) made up the majority of the series, and half of these were extranodal marginal zone lymphomas (ENMZL, N=7). Ten patients received systemic chemotherapy with (N=3) or without rituximab (N=7), and 4 of these received additional local therapy. The others received radiotherapy (N=3) or endoscopic mucosal resection (N=3). Twelve patients (75%) achieved complete response (CR) after first-line treatment. Event-free survival (EFS) and overall survival (OS) in stages IE and IIE were significantly longer compared with stages IVE (P=0.001 and P=0.001, respectively). All patients with ENMZL (N=7) achieved CR during or after initial treatment.
CONCLUSION
PRL is very rare and seems to present mostly as B-cell type. Stage is the most important prognostic factor, with significantly better survival associated with localized diseases. ENMZL may be one of the most common types of PRL with favorable treatment outcomes.

Keyword

Lymphoma; Rectum; Treatment; Prognosis

MeSH Terms

B-Lymphocytes
Chungcheongnam-do
Cohort Studies
Consensus
Disease-Free Survival
Drug Therapy
Humans
Korea
Lymphoma*
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Prognosis
Radiotherapy
Rectum
Retrospective Studies
Rituximab
Seoul
Rituximab

Figure

• 

  Fig. 1 Event-free survival and overall survival according to stage.

• 

  Fig. 2 Event-free survival and overall survival according to histologic subtype.

Reference

1. Zucca E, Roggero E, Bertoni F, Cavalli F. Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol. 1997; 8:727–737. PMID: 9332679.

2. Lewin KJ, Ranchod M, Dorfman RF. Lymphomas of the gastrointestinal tract: a study of 117 cases presenting with gastrointestinal disease. Cancer. 1978; 42:693–707. PMID: 354774.

3. Dragosics B, Bauer P, Radaszkiewicz T. Primary gastrointestinal non-Hodgkin's lymphomas. A retrospective clinicopathologic study of 150 cases. Cancer. 1985; 55:1060–1073. PMID: 3881161.

4. Henry CA, Berry RE. Primary lymphoma of the large intestine. Am Surg. 1988; 54:262–266. PMID: 3364860.

5. Dodd GD. Lymphoma of the hollow abdominal viscera. Radiol Clin North Am. 1990; 28:771–783. PMID: 2190270.

6. Chihara D, Kagami Y, Oki Y, et al. R-CHOP therapy for MALT lymphoma of the rectum. Eur J Haematol. 2010; 84:84–86. PMID: 19737307.

7. Unal B, Karabeyoglu M, Erel S, Bozkurt B, Kocer B, Cengiz O. Primary rectal lymphoma: an unusual treatment for a rare case. Postgrad Med J. 2008; 84:333–335. PMID: 18644928.

8. Bilsel Y, Balik E, Yamaner S, Bugra D. Clinical and therapeutic considerations of rectal lymphoma: a case report and literature review. World J Gastroenterol. 2005; 11:460–461. PMID: 15637770.

9. Cheson BD, Horning SJ, Coiffier B, et al. NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999; 17:1244. PMID: 10561185.

10. Kim YH, Lee JH, Yang SK, et al. Primary colon lymphoma in Korea: a KASID (Korean Association for the Study of Intestinal Diseases) Study. Dig Dis Sci. 2005; 50:2243–2247. PMID: 16416168.

11. Fan CW, Changchien CR, Wang JY, et al. Primary colorectal lymphoma. Dis Colon Rectum. 2000; 43:1277–1282. PMID: 11005497.

12. Shepherd FA, Evans WK, Kutas G, et al. Chemotherapy following surgery for stages IE and IIE non-Hodgkin's lymphoma of the gastrointestinal tract. J Clin Oncol. 1988; 6:253–260. PMID: 3339394.

13. Lai YL, Lin JK, Liang WY, Huang YC, Chang SC. Surgical resection combined with chemotherapy can help achieve better outcomes in patients with primary colonic lymphoma. J Surg Oncol. 2011; 104:265–268. PMID: 21472731.

14. Bellesi G, Alterini R, Messori A, et al. Combined surgery and chemotherapy for the treatment of primary gastrointestinal intermediate- or high-grade non-Hodgkin's lymphomas. Br J Cancer. 1989; 60:244–248. PMID: 2765374.

15. Rackner VL, Thirlby RC, Ryan JA Jr. Role of surgery in multimodality therapy for gastrointestinal lymphoma. Am J Surg. 1991; 161:570–575. PMID: 2031540.